IS7915A - Process for the production of doloxetine and intermediates for use in the process - Google Patents

Process for the production of doloxetine and intermediates for use in the process

Info

Publication number
IS7915A
IS7915A IS7915A IS7915A IS7915A IS 7915 A IS7915 A IS 7915A IS 7915 A IS7915 A IS 7915A IS 7915 A IS7915 A IS 7915A IS 7915 A IS7915 A IS 7915A
Authority
IS
Iceland
Prior art keywords
acid addition
addition salt
duloxetine
doloxetine
intermediates
Prior art date
Application number
IS7915A
Other languages
Icelandic (is)
Inventor
Ramachandra Rao Dharmaraj
Narayanrao Kankan Rajendra
Original Assignee
Cipla Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd. filed Critical Cipla Ltd.
Publication of IS7915A publication Critical patent/IS7915A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A process for making (+)duloxetine or an acid addition salt thereof, comprising reacting intermediate compounds of formulae (I) and (II) so as to yield a compound of formula (III), or an acid addition salt thereof in the presence of a base and a phase transfer catalyst, where one of X and Y is hydroxy and the other is a leaving group, and subjecting a compound of formula (III), or an acid addition salt thereof, to further process steps so as to yield (+) duloxetine, or an acid addition salt thereof, substantially free of (-)duloxetine.
IS7915A 2002-12-19 2005-06-24 Process for the production of doloxetine and intermediates for use in the process IS7915A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0229583.0A GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein
PCT/GB2003/005357 WO2004056795A1 (en) 2002-12-19 2003-12-10 A process for preparing duloxetine and intermediates for use therein

Publications (1)

Publication Number Publication Date
IS7915A true IS7915A (en) 2005-06-24

Family

ID=9949985

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7915A IS7915A (en) 2002-12-19 2005-06-24 Process for the production of doloxetine and intermediates for use in the process

Country Status (24)

Country Link
US (1) US7645890B2 (en)
EP (2) EP1690861B1 (en)
JP (1) JP5259048B2 (en)
KR (1) KR100926723B1 (en)
CN (2) CN101125848B (en)
AT (1) ATE353081T1 (en)
AU (2) AU2003292396B2 (en)
BR (1) BR0316902A (en)
CA (1) CA2510750A1 (en)
DE (1) DE60311599T2 (en)
ES (1) ES2279971T3 (en)
GB (1) GB0229583D0 (en)
HR (1) HRP20050657A2 (en)
IL (1) IL169232A (en)
IS (1) IS7915A (en)
MA (1) MA27706A1 (en)
MX (1) MXPA05006659A (en)
NZ (2) NZ540881A (en)
PL (1) PL377380A1 (en)
PT (1) PT1587801E (en)
RU (1) RU2351594C2 (en)
TN (1) TNSN05167A1 (en)
WO (1) WO2004056795A1 (en)
ZA (1) ZA200505656B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027798A2 (en) * 2004-08-05 2006-03-16 Sun Pharmaceutical Industries Limited A process for preparation of an antidepressant compound
CZ297560B6 (en) * 2004-10-26 2007-02-07 Zentiva, A. S. Process for preparing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
WO2006081515A2 (en) * 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs
EP1856087A1 (en) 2005-03-08 2007-11-21 Teva Pharmaceutical Industries Limited Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
US20060270861A1 (en) 2005-03-14 2006-11-30 Santiago Ini Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
WO2007038253A2 (en) * 2005-09-22 2007-04-05 Teva Pharmaceutical Industries Ltd. Dnt-maleate and methods of preparation thereof
EP2100888A3 (en) * 2005-12-05 2011-01-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of duloxetine hydrochloride
WO2007096707A2 (en) * 2005-12-12 2007-08-30 Medichem S.A. Improved synthesis and preparations of duloxetine salts
CZ299270B6 (en) 2006-01-04 2008-06-04 Zentiva, A. S. Process for preparing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride
WO2007077580A2 (en) * 2006-01-06 2007-07-12 Msn Laboratories Limited Improved process for pure duloxetine hydrochloride
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine
US20070238883A1 (en) * 2006-02-13 2007-10-11 Santiago Ini Process for the preparation of(s)-(+)-N,N-dimethyl-3-(1-Naphthalenyloxy)-3-(2-Thienyl)propanamine, A duloxetine intermediate
HU228458B1 (en) * 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
ATE474832T1 (en) 2006-05-05 2010-08-15 Fidia Farmaceutici METHOD FOR PRODUCING AN INTERMEDIATE FOR THE ASYMMETRIC SYNTHESIS OF (+)DULOXETINE
EP1934197A2 (en) * 2006-05-23 2008-06-25 Teva Pharmaceutical Industries Ltd Duloxetine hcl polymorphs
EP2044049A2 (en) 2006-07-03 2009-04-08 Ranbaxy Laboratories Limited Process for the preparation of enantiomerically pure salts of n-methyl- 3 -( 1-naph-thaleneoxy)- 3 - (-2-thienyl) propanamine
CZ300116B6 (en) * 2006-12-05 2009-02-11 Zentiva, A. S. Purification process of (S)-N-methyl-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride
HU227730B1 (en) 2006-12-22 2012-01-30 Richter Gedeon Nyrt Process for the preparation of duloxetine and for their the intermediates
EP2114912B1 (en) 2006-12-22 2012-04-04 Synthon B.V. Process for making duloxetine and related compounds
EP2132192B1 (en) 2007-03-05 2013-04-24 Lupin Limited Novel process for preparation of duloxetine hydrochloride
WO2009019719A2 (en) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Process for the preparation of 3-aryloxy-3-arylpropanamines
WO2009130708A2 (en) * 2008-04-22 2009-10-29 Shodhana Laboratories Limited Preparation of duloxetine and its salts
WO2010025287A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2010025238A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2011033366A2 (en) 2009-09-16 2011-03-24 Jubilant Life Sciences Limited Process for the preparation of duloxetine hydrochloride and its precursors
CN103360365A (en) * 2012-04-06 2013-10-23 李晓红 New preparation process of medicinal raw material duloxetine hydrochloride of antidepressant drug
CN104230882B (en) * 2014-08-29 2017-03-08 宁波美诺华药业股份有限公司 A kind of preparation method of duloxetine hydrochloride impurity
CN104829587B (en) * 2015-05-08 2017-07-21 上海万巷制药有限公司 The preparation of duloxetine hydrochloride
CN107382958B (en) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 Crystallization method of duloxetine intermediate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH578532A5 (en) * 1971-08-03 1976-08-13 Cassella Farbwerke Mainkur Ag
FI77018C (en) 1980-11-14 1989-01-10 Lilly Co Eli ANALOGIFICATION OF THE ANTIDEPRESSIVE ACTIVATED (-) - ENANTIERS OF N-METHYL-N- / 3- (2-METHYLPHENOXY) -3-PHENYLPROPYL / AMINE OCH DESS PHARMACEUTICAL PRODUCT OF SALT.
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
JPS62286959A (en) * 1986-06-05 1987-12-12 Seitetsu Kagaku Co Ltd Production of optically active cyanocarnitine salt
KR880007433A (en) * 1986-12-22 1988-08-27 메리 앤 터커 3-aryloxy-3-substituted propanamine
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA2042346A1 (en) 1990-05-17 1991-11-18 Michael Alexander Staszak Chiral synthesis of 1-aryl-3-aminopropan-1-ols
JPH09176157A (en) * 1992-12-09 1997-07-08 Takeda Chem Ind Ltd Optically active aminocoumaran derivative
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US6458955B1 (en) * 1994-12-16 2002-10-01 Uop Llc Process for preparation of pharmaceutically desired enantiomers
US6162949A (en) * 1994-12-16 2000-12-19 Uop Llc Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
IL139592A (en) * 1998-05-22 2005-08-31 Lilly Co Eli Pharmaceutical composition containing an atypical antipsychotic and a serotonin reuptake inhibitor for combination therapy of refractory depression
JP2002529499A (en) * 1998-11-13 2002-09-10 イーライ・リリー・アンド・カンパニー How to treat pain
JP2002541235A (en) * 1999-04-09 2002-12-03 イーライ・リリー・アンド・カンパニー Method for producing 3-aryloxy-3-arylpropylamine and intermediates thereof
WO2001044166A1 (en) * 1999-12-17 2001-06-21 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
US20040249170A1 (en) * 2002-01-24 2004-12-09 Alfio Borghese Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine

Also Published As

Publication number Publication date
JP5259048B2 (en) 2013-08-07
WO2004056795A8 (en) 2005-08-11
DE60311599D1 (en) 2007-03-22
ATE353081T1 (en) 2007-02-15
PL377380A1 (en) 2006-02-06
ES2279971T3 (en) 2007-09-01
EP1690861B1 (en) 2012-09-12
DE60311599T2 (en) 2007-10-25
RU2005122662A (en) 2006-01-20
KR20050089839A (en) 2005-09-08
PT1587801E (en) 2007-04-30
MA27706A1 (en) 2006-01-02
NZ540881A (en) 2008-09-26
CN101125848A (en) 2008-02-20
JP2006514030A (en) 2006-04-27
WO2004056795A1 (en) 2004-07-08
AU2010200142A1 (en) 2010-02-04
NZ569874A (en) 2009-11-27
RU2351594C2 (en) 2009-04-10
CN101125848B (en) 2012-09-12
IL169232A (en) 2010-02-17
EP1587801B1 (en) 2007-01-31
AU2010200142B2 (en) 2012-04-12
GB0229583D0 (en) 2003-01-22
EP1587801A1 (en) 2005-10-26
HRP20050657A2 (en) 2005-10-31
EP1690861A2 (en) 2006-08-16
US7645890B2 (en) 2010-01-12
EP1690861A3 (en) 2006-09-06
AU2003292396A1 (en) 2004-07-14
BR0316902A (en) 2005-10-25
ZA200505656B (en) 2006-04-26
CN1747947A (en) 2006-03-15
AU2003292396B2 (en) 2010-05-20
US20060205956A1 (en) 2006-09-14
TNSN05167A1 (en) 2007-05-14
CN100579975C (en) 2010-01-13
MXPA05006659A (en) 2006-02-22
CA2510750A1 (en) 2004-07-08
KR100926723B1 (en) 2009-11-16

Similar Documents

Publication Publication Date Title
IS7915A (en) Process for the production of doloxetine and intermediates for use in the process
WO2006004100A8 (en) Method for producing 1,2-dihydropyridine-2-one compound
SI1781683T1 (en) Process for the preparation of 17-vinyl- triflates as intermediates
NZ598172A (en) Synthesis of boronic ester and acid compounds
TNSN05111A1 (en) Process for the preparation of (s,s) -cis -2- benzhydryl -3- benzylaminoquinuclidine
TW200726754A (en) Chemical process
ATE517857T1 (en) PRODUCTION OF 4-PHENYLBUTANIC ACID
MXPA03005429A (en) Method for producing sulfonamide-substituted imidazotriazinones.
MA29690B1 (en) PROCESS FOR THE PREPARATION OF 4BETA-AMINO-4'-DEMETHYL-4-DESOXYPODOPHYLLOTOXIN
EA200701470A1 (en) METHODS OF OBTAINING DERIVATIVES OF 4- (FENOXY-5-METHYLPYRIMIDIN-4-ILOXI) PIPERIDIN-1-CARBIC ACID AND RELATED COMPOUNDS
EP1484301A4 (en) PROCESS FOR PRODUCING trans-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVE
BR0213814A (en) Processes for the manufacture of 3-hydroxy-n, 1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
AU2002220596A1 (en) Synthesis of r(+)alpha-lipoic acid
DE60102008D1 (en) PRODUCTION PROCESS FOR A KNOWN TERAZOLE DERIVATIVE
BRPI0507422A (en) process for production of 2,5-dimethylphenylacetic acid
IL151449A0 (en) Method for production of spirocyclic tetronic acid derivatives
EA200000924A3 (en) Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof
EP1215206A4 (en) Processes for the preparation of 4(5)-amino-5(4)-carboxamidoimidazoles and intermediates thereof
RU2003122994A (en) COMPLEX COMPOUND OF 6-METHYLURACYL WITH AMBERIC ACID, MANIFESTING ANTI-HYPOXIC ACTIVITY AND METHOD FOR ITS PRODUCTION
GB0229688D0 (en) Solid-phase preparation of [18F] Fluorohaloalkanes
NO20055991L (en) Process for Synthesizing Heterocyclic Compounds
EP0658542A4 (en) PROCESS FOR PRODUCING -g (a) -HYDROXYIMINOPHENYLACETONITRILE.
PT1566381E (en) Process for production of 1- 2-(benzimidazol-2-yl- thio)ethyl piperazine or salts thereof
EP1544196A4 (en) PROCESS FOR PRODUCING GAMMA-CETO-ACETALS
DE60336739D1 (en) PROCESS FOR PREPARING A 2-SUBSTITUTED PYRIDINE DERIVATIVE